PMID
Data
Article Title
Organization
Isolation and structure of SCH 351633: a novel hepatitis C virus (HCV) NS3 protease inhibitor from the fungus Penicillium griseofulvum.

Schering-Plough Research Institute
Phenylalanine and Phenylglycine Analogues as Arginine Mimetics in Dengue Protease Inhibitors.

Heidelberg University
Dual inhibitors of the dengue and West Nile virus NS2B-NS3 proteases: Synthesis, biological evaluation and docking studies of novel peptide-hybrids.

Heidelberg University
Discovery of HCV NS5B thumb site I inhibitors: core-refining from benzimidazole to indole scaffold.

Shandong University
Vinylated linear P2 pyrimidinyloxyphenylglycine based inhibitors of the HCV NS3/4A protease and corresponding macrocycles.

TBA
Identification of novel thiadiazoloacrylamide analogues as inhibitors of dengue-2 virus NS2B/NS3 protease.

China Pharmaceutical University
A perspective on targeting non-structural proteins to combat neglected tropical diseases: Dengue, West Nile and Chikungunya viruses.

University of Kwazulu-Natal
C-terminal residue optimization and fragment merging: discovery of a potent Peptide-hybrid inhibitor of dengue protease.

Heidelberg University
Structure-based design of a novel series of azetidine inhibitors of the hepatitis C virus NS3/4A serine protease.

Idenix Pharmaceuticals
Macrocyclic inhibitors of 3C and 3C-like proteases of picornavirus, norovirus, and coronavirus.

Wichita State University
Synthesis and evaluation of tripeptidyl alpha-ketoamides as human rhinovirus 3C protease inhibitors.

Eli Lilly
Synthesis and biological characterization of B-ring amino analogues of potent benzothiadiazine hepatitis C virus polymerase inhibitors.

Abbott Laboratories
Phenylglycine as a novel P2 scaffold in hepatitis C virus NS3 protease inhibitors.

Uppsala University
Synthesis and antiviral activity of 5-substituted cytidine analogues: identification of a potent inhibitor of viral RNA-dependent RNA polymerases.

The Pennsylvania State University
Improved replicon cellular activity of non-nucleoside allosteric inhibitors of HCV NS5B polymerase: from benzimidazole to indole scaffolds.

Boehringer Ingelheim Pharmaceuticals
Inhibitory activity of cyclohexenyl chalcone derivatives and flavonoids of fingerroot, Boesenbergia rotunda (L.), towards dengue-2 virus NS3 protease.

Sunway University College
Design and synthesis of depeptidized macrocyclic inhibitors of hepatitis C NS3-4A protease using structure-based drug design.

Schering-Plough Research Institute
Control of hepatitis C: a medicinal chemistry perspective.

University of Wollongong
Antiviral compounds from traditional Chinese medicines Galla Chinese as inhibitors of HCV NS3 protease.

Peking University
Solid-phase library synthesis, screening, and selection of tight-binding reduced peptide bond inhibitors of a recombinant Leishmania mexicana cysteine protease B.

Carlsberg Laboratory
Protease inhibitors: current status and future prospects.

University of Queensland
Specific inhibition of HIV-1 protease by boronated porphyrins.

University of California
HIV protease: a novel chemotherapeutic target for AIDS.

Merck Sharp and Dohme Research Laboratories
Inhibition of hepatitis C virus NS3 protease activity by product-based peptides is dependent on helicase domain.

Uppsala University
NMR line-broadening and transferred NOESY as a medicinal chemistry tool for studying inhibitors of the hepatitis C virus NS3 protease domain.

Boehringer Ingelheim Pharmaceuticals
Highly potent and selective peptide-based inhibitors of the hepatitis C virus serine protease: towards smaller inhibitors.

Boehringer Ingelheim Pharmaceuticals
Peptide-based inhibitors of the hepatitis C virus serine protease.

Boehringer Ingelheim (Canada)
Peptidomimetic inhibitors of human immunodeficiency virus protease (HIV-PR): Design, enzyme binding and selectivity, antiviral efficacy, and cell permeability properties

TBA
Structure-activity relationship and improved hydrolytic stability of pyrazole derivatives that are allosteric inhibitors of West Nile Virus NS2B-NS3 proteinase.

Sanford-Burnham Medical Research Institute
Non-nucleoside inhibitors of HCV polymerase NS5B. Part 3: synthesis and optimization studies of benzothiazine-substituted tetramic acids.

Roche Palo Alto
Non-nucleoside inhibitors of HCV polymerase NS5B. Part 4: structure-based design, synthesis, and biological evaluation of benzo[d]isothiazole-1,1-dioxides.

Roche Palo Alto
Inhibition of human cytomegalovirus protease by benzoxazinones and evidence of antiviral activity in cell culture

TBA
Inhibition of human rhinovirus 3C protease by homophthalimides

TBA
Synthesis and activity of conformationally-constrained macrocyclic norstatine-based inhibitors of HIV protease

TBA
Novel, selective mechanism-based inhibitors of the herpes proteases

TBA
Glutamine-derived aldehydes for the inhibition of human rhinovirus 3C protease

TBA
Structure-activity relationships of heteroaromatic esters as human rhinovirus 3C protease inhibitors.

Institute of Science and Technology
Identification of halosalicylamide derivatives as a novel class of allosteric inhibitors of HCV NS5B polymerase.

Abbott Laboratories
Perspectives on the current antiviral developments towards RNA-dependent RNA polymerase (RdRp) and methyltransferase (MTase) domains of dengue virus non-structural protein 5 (DENV-NS5).

Csir-Indian Institute of Chemical Technology (CSIR-IICT)
Recent two-year advances in anti-dengue small-molecule inhibitors.

Macao University of Science and Technology
Discovery of dehydroandrographolide derivatives with C19 hindered ether as potent anti-ZIKV agents with inhibitory activities to MTase of ZIKV NS5.

Nanjing Tech University
N-sulfonyl peptide-hybrids as a new class of dengue virus protease inhibitors.

Heidelberg University
Designing photoaffinity tool compounds for the investigation of the DENV NS2B-NS3 protease allosteric binding pocket.

Johannes Gutenberg-University
Design, synthesis, and biological evaluation of novel 2'-methyl-2'-fluoro-6-methyl-7-alkynyl-7-deazapurine nucleoside analogs as anti-Zika virus agents.

Guangzhou Institutes of Biomedicine and Health
Isatin compounds as noncovalent SARS coronavirus 3C-like protease inhibitors.

Peking University
P2-P4 macrocyclic inhibitors of hepatitis C virus NS3-4A serine protease.

Schering-Plough Research Institute
Discovery of proline sulfonamides as potent and selective hepatitis C virus NS5b polymerase inhibitors. Evidence for a new NS5b polymerase binding site.

Wyeth Research
SAR evolution towards potent C-terminal carboxamide peptide inhibitors of Zika virus NS2B-NS3 protease.

Irbm
Insights on Dengue and Zika NS5 RNA-dependent RNA polymerase (RdRp) inhibitors.

Federal University of Alagoas
SAR and mode of action of novel non-nucleoside inhibitors of hepatitis C NS5b RNA polymerase.

Amgen
3-(1,1-dioxo-2H-(1,2,4)-benzothiadiazin-3-yl)-4-hydroxy-2(1H)-quinolinones, potent inhibitors of hepatitis C virus RNA-dependent RNA polymerase.

Glaxosmithkline
Design and synthesis of 3,4-dihydro-1H-[1]-benzothieno[2,3-c]pyran and 3,4-dihydro-1H-pyrano[3,4-b]benzofuran derivatives as non-nucleoside inhibitors of HCV NS5B RNA dependent RNA polymerase.

Wyeth Research
Peptide inhibitors of dengue virus NS3 protease. Part 2: SAR study of tetrapeptide aldehyde inhibitors.

Novartis Institute For Tropical Diseases
Peptide inhibitors of Dengue virus NS3 protease. Part 1: Warhead.

Novartis Institute For Tropical Diseases
Design, synthesis, and biological activity of m-tyrosine-based 16- and 17-membered macrocyclic inhibitors of hepatitis C virus NS3 serine protease.

Schering-Plough Research Institute
Synthesis and biological activity of macrocyclic inhibitors of hepatitis C virus (HCV) NS3 protease.

Schering-Plough Research Institute
Investigation of glycine alpha-ketoamide HCV NS3 protease inhibitors: effect of carboxylic acid isosteres.

Pharmaceutical Research Institute
Discovery of potent benzoxaborole inhibitors against SARS-CoV-2 main and dengue virus proteases.

Heidelberg University
Anchor-GRIND: filling the gap between standard 3D QSAR and the GRid-INdependent descriptors.

Imim/Universitat Pompeu Fabra
Seeking heterocyclic scaffolds as antivirals against dengue virus.

National Institute of Technology
A short survey of dengue protease inhibitor development in the past 6 years (2015-2020) with an emphasis on similarities between DENV and SARS-CoV-2 proteases.

Birla Institute of Technology
The design and enzyme-bound crystal structure of indoline based peptidomimetic inhibitors of hepatitis C virus NS3 protease.

Mrl Rome
Nanoparticular Inhibitors of Flavivirus Proteases from Zika, West Nile and Dengue Virus Are Cell-Permeable Antivirals.

Freie Universit£T Berlin
Identification and In Silico Binding Study of a Highly Potent DENV NS2B-NS3 Covalent Inhibitor.

Shenyang Pharmaceutical University
P4 and P1' optimization of bicycloproline P2 bearing tetrapeptidyl alpha-ketoamides as HCV protease inhibitors.

Eli Lilly
P4 cap modified tetrapeptidyl alpha-ketoamides as potent HCV NS3 protease inhibitors.

Eli Lilly
Structural variations in keto-glutamines for improved inhibition against hepatitis A virus 3C proteinase.

University of Alberta
Synthesis, structure-activity relationship and antiviral activity of indole-containing inhibitors of Flavivirus NS2B-NS3 protease.

Baylor College of Medicine
Amidoxime prodrugs convert to potent cell-active multimodal inhibitors of the dengue virus protease.

Griffith University
Non-peptidic small-molecule inhibitors of the single-chain hepatitis C virus NS3 protease/NS4A cofactor complex discovered by structure-based NMR screening.

Schering-Plough Research Institute
The spectrum between substrates and inhibitors: Pinpointing the binding mode of dengue protease ligands with modulated basicity and hydrophobicity.

Heidelberg University
Capped dipeptide phenethylamide inhibitors of the HCV NS3 protease.

Irbm, Mrl Rome
Inhibitors of hepatitis C virus NS3.4A protease 2. Warhead SAR and optimization.

Vertex Pharmaceuticals
Discovery of thiophene-2-carboxylic acids as potent inhibitors of HCV NS5B polymerase and HCV subgenomic RNA replication. Part 2: tertiary amides.

Shire Biochem
Discovery of thiophene-2-carboxylic acids as potent inhibitors of HCV NS5B polymerase and HCV subgenomic RNA replication. Part 1: Sulfonamides.

Shire Biochem
NMR structural characterization of peptide inhibitors bound to the Hepatitis C virus NS3 protease: design of a new P2 substituent.

Boehringer Ingelheim (Canada)
Novel P4 truncated tripeptidyl alpha-ketoamides as HCV protease inhibitors.

Eli Lilly
P1 and P3 optimization of novel bicycloproline P2 bearing tetrapeptidyl alpha-ketoamide based HCV protease inhibitors.

Eli Lilly
Discovery of a novel bicycloproline P2 bearing peptidyl alpha-ketoamide LY514962 as HCV protease inhibitor.

Eli Lilly
SAR of novel benzothiazoles targeting an allosteric pocket of DENV and ZIKV NS2B/NS3 proteases.

Johannes Gutenberg-University
Non-nucleoside inhibitors of the hepatitis C virus NS5B polymerase: discovery and preliminary SAR of benzimidazole derivatives.

Boehringer Ingelheim (Canada)
Application of the lambda-dynamics method to evaluate the relative binding free energies of inhibitors to HCV protease.

Schering-Plough Research Institute
Two antiviral compounds from the plant Stylogne cauliflora as inhibitors of HCV NS3 protease.

Schering-Plough Research Institute
Design and synthesis of pyrrolidine-5,5'-trans-lactams (5-oxo-hexahydropyrrolo[3,2-b]pyrroles) as novel mechanism-based inhibitors of human cytomegalovirus protease. 4. Antiviral activity and plasma stability.

Glaxosmithkline
Pyrimido[1,2-b]-1,2,4,5-tetrazin-6-ones as HCMV protease inhibitors: a new class of heterocycles with flavin-like redox properties.

Wyeth Research
Further SAR studies on novel small molecule inhibitors of the hepatitis C (HCV) NS5B polymerase.

Shire Biochem
Beyond Basicity: Discovery of Nonbasic DENV-2 Protease Inhibitors with Potent Activity in Cell Culture.

Heidelberg University
Synthesis, Structure-Activity Relationships, and Antiviral Activity of Allosteric Inhibitors of Flavivirus NS2B-NS3 Protease.

Baylor College of Medicine
Novel, potent phenethylamide inhibitors of the hepatitis C virus (HCV) NS3 protease: probing the role of P2 aryloxyprolines with hybrid structures.

Mrl Rome
Design and synthesis of potent, non-peptide inhibitors of HCV NS3 protease.

Bristol-Myers Squibb
Glycine alpha-ketoamides as HCV NS3 protease inhibitors.

Pharmaceutical Research Institute
Design and synthesis of bicyclic pyrimidinone-based HCV NS3 protease inhibitors.

Bristol-Myers Squibb Pharmaceutical Research Institute
Phenethyl amides as novel noncovalent inhibitors of hepatitis C virus NS3/4A protease: discovery, initial SAR, and molecular modeling.

Mrl Rome
P1 Phenethyl peptide boronic acid inhibitors of HCV NS3 protease.

Bristol-Myers Squibb Pharmaceutical Research Institute
Pyrrolidine-5,5-trans-lactams as novel mechanism-based inhibitors of human cytomegalovirus protease. Part 3: potency and plasma stability.

Glaxosmithkline
Structure-based design of a parallel synthetic array directed toward the discovery of irreversible inhibitors of human rhinovirus 3C protease.

Pfizer
Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 6. Structure-activity studies of orally bioavailable, 2-pyridone-containing peptidomimetics.

Agouron Pharmaceuticals
Azapeptides as inhibitors of the hepatitis C virus NS3 serine protease.

Schering-Plough Research Institute
Evolution, synthesis and SAR of tripeptide alpha-ketoacid inhibitors of the hepatitis C virus NS3/NS4A serine protease.

Irbm, Mrl Rome
Solution and solid-phase synthesis of potent inhibitors of hepatitis C virus NS3 proteinase.

Roche Discovery Welwyn
Design and synthesis of pyrrolidine-5,5-trans-lactams (5-oxohexahydropyrrolo[3,2-b]pyrroles) as novel mechanism-based inhibitors of human cytomegalovirus protease. 2. Potency and chirality.

Glaxosmithkline
Discovery, total synthesis, HRV 3C-protease inhibitory activity, and structure-activity relationships of 2-methoxystypandrone and its analogues.

Merck Research Laboratories
Structure-activity relationship studies of a bisbenzimidazole-based, Zn(2+)-dependent inhibitor of HCV NS3 serine protease.

Bristol-Myers Squibb Pharmaceutical Research Institute
A New Class of Dengue and West Nile Virus Protease Inhibitors with Submicromolar Activity in Reporter Gene DENV-2 Protease and Viral Replication Assays.

Heidelberg University
Inhibitors of the Zika virus protease NS2B-NS3.

Australian National University
Arylalkylidene rhodanine with bulky and hydrophobic functional group as selective HCV NS3 protease inhibitor.

Institute of Molecular and Cell Biology
Catching a Moving Target: Comparative Modeling of Flaviviral NS2B-NS3 Reveals Small Molecule Zika Protease Inhibitors.

Freie Universit£T Berlin
Design and synthesis of pyrrolidine-5,5-trans-lactams (5-oxo-hexahydro-pyrrolo[3,2-b]pyrroles) as novel mechanism-based inhibitors of human cytomegalovirus protease. 1. The alpha-methyl-trans-lactam template.

Glaxo Wellcome Research and Development
Metal mediated protease inhibition: design and synthesis of inhibitors of the human cytomegalovirus (hCMV) protease.

Smithkline Beecham Pharmaceuticals
Synthesis of potent and broad genotypically active NS5B HCV non-nucleoside inhibitors binding to the thumb domain allosteric site 2 of the viral polymerase.

Idenix Sarl, An Msd
The Medicinal Chemistry of Dengue Virus.

Heidelberg University
Substituted benzamide inhibitors of human rhinovirus 3C protease: structure-based design, synthesis, and biological evaluation.

Agouron Pharmaceuticals
Alpha-ketoamides, alpha-ketoesters and alpha-diketones as HCV NS3 protease inhibitors.

Dupont Pharmaceuticals
2-chloro-3-substituted-1,4-naphthoquinone inactivators of human cytomegalovirus protease.

Glaxowellcome Medicines Research Centre
Recent update on anti-dengue drug discovery.

Queensland University of Technology
Backbone modifications in peptidic inhibitors of flaviviral proteases.

Heidelberg University
Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 4. Incorporation of P1 lactam moieties as L-glutamine replacements.

Agouron Pharmaceuticals
Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 3. Structure-activity studies of ketomethylene-containing peptidomimetics.

Agouron Pharmaceuticals
Inhibition of human cytomegalovirus protease by enedione derivatives of thieno[2,3-d]oxazinones through a novel dual acylation/alkylation mechanism.

Smithkline Beecham Pharmaceuticals
Inhibition of herpes proteases and antiviral activity of 2-substituted thieno[2,3-d]oxazinones.

Smithkline Beecham Pharmaceuticals
Peptide-β-lactam Inhibitors of Dengue and West Nile Virus NS2B-NS3 Protease Display Two Distinct Binding Modes.

Heidelberg University
Fluorine and Fluorinated Motifs in the Design and Application of Bioisosteres for Drug Design.

Bristol-Myers Squibb
Design and synthesis of dipeptidyl alpha',beta'-epoxy ketones, potent irreversible inhibitors of the cysteine protease cruzain.

University of Michigan
Prodrug Activation by a Viral Protease: Evaluating Combretastatin Peptide Hybrids To Selectively Target Infected Cells.

Heidelberg University
Design, Synthesis, and Anti-RNA Virus Activity of 6'-Fluorinated-Aristeromycin Analogues.

Seoul National University
Drugs for the Treatment of Zika Virus Infection.

University of North Carolina At Chapel Hill
Peptide derivatives as inhibitors of NS2B-NS3 protease from Dengue, West Nile, and Zika flaviviruses.

Federal University of Alagoas
Synthesis and structure-activity relationships of small-molecular di-basic esters, amides and carbamates as flaviviral protease inhibitors.

Heidelberg University
beta-Lactam derivatives as inhibitors of human cytomegalovirus protease.

Boehringer Ingelheim (Canada)
Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 1. Michael acceptor structure-activity studies.

Agouron Pharmaceuticals
Tripeptide aldehyde inhibitors of human rhinovirus 3C protease: design, synthesis, biological evaluation, and cocrystal structure solution of P1 glutamine isosteric replacements.

Agouron Pharmaceuticals
Proline-Based Allosteric Inhibitors of Zika and Dengue Virus NS2B/NS3 Proteases.

Johannes Gutenberg University Mainz
Discovery of Nonstandard Macrocyclic Peptides as Noncompetitive Inhibitors of the Zika Virus NS2B-NS3 Protease.

Australian National University
Peptidomimetic inhibitors of the human cytomegalovirus protease.

Boehringer Ingelheim
Optimization of a fragment linking hit toward Dengue and Zika virus NS5 methyltransferases inhibitors.

Cnrs Umr7258
Potent noncovalent thrombin inhibitors that utilize the unique amino acid D-dicyclohexylalanine in the P3 position. Implications on oral bioavailability and antithrombotic efficacy.

Merck Research Laboratories
Design, synthesis, and evaluation of nonpeptidic inhibitors of human rhinovirus 3C protease.

Agouron Pharmaceuticals
Phenylthiomethyl Ketone-Based Fragments Show Selective and Irreversible Inhibition of Enteroviral 3C Proteases.

Freie Universit£T Berlin
2,3,4-Trihydroxybenzyl-hydrazide analogues as novel potent coxsackievirus B3 3C protease inhibitors.

Gwangju Institute of Science and Technology (Gist)
Achiral pyrazinone-based inhibitors of the hepatitis C virus NS3 protease and drug-resistant variants with elongated substituents directed toward the S2 pocket.

Uppsala University
Novel Peptidomimetic Hepatitis C Virus NS3/4A Protease Inhibitors Spanning the P2-P1' Region.

Uppsala University
Discovery of danoprevir (ITMN-191/R7227), a highly selective and potent inhibitor of hepatitis C virus (HCV) NS3/4A protease.

Array Biopharma
Novel Quinoline-Based P2-P4 Macrocyclic Derivatives As Pan-Genotypic HCV NS3/4a Protease Inhibitors.

Merck Research Laboratories
Haloperidol-based irreversible inhibitors of the HIV-1 and HIV-2 proteases.

University of California
Development of macrocyclic inhibitors of HCV NS3/4A protease with cyclic constrained P2-P4 linkers.

Merck Research Laboratories
Development of anti-coxsackievirus agents targeting 3C protease.

Gwangju Institute of School of Life Sciences
Discovery of MK-5172, a Macrocyclic Hepatitis C Virus NS3/4a Protease Inhibitor.

Merck Research Laboratories
Synthesis and evaluation of pyrazolone compounds as SARS-coronavirus 3C-like protease inhibitors.

Academia Sinica
Discovery of achiral inhibitors of the hepatitis C virus NS3 protease based on 2(1H)-pyrazinones.

Uppsala University
Improved P2 phenylglycine-based hepatitis C virus NS3 protease inhibitors with alkenylic prime-side substituents.

Uppsala University
Targeting the protease of West Nile virus.

Australian National University Canberra
Novel inhibitors of dengue virus methyltransferase: discovery by in vitro-driven virtual screening on a desktop computer grid.

University of Basel
Phenotypic characterization of resistant Val36 variants of hepatitis C virus NS3-4A serine protease.

Vertex Pharmaceuticals
Phenotypic and structural analyses of hepatitis C virus NS3 protease Arg155 variants: sensitivity to telaprevir (VX-950) and interferon alpha.

Vertex Pharmaceuticals
In silico fragment-based drug design with SEED.

University of Z£Rich
4-Iminooxazolidin-2-one as a Bioisostere of the Cyanohydrin Moiety: Inhibitors of Enterovirus 71 3C Protease.

Nankai University
Functionalized 2,1-benzothiazine 2,2-dioxides as new inhibitors of Dengue NS5 RNA-dependent RNA polymerase.

University of Perugia
Identification of quinone analogues as potential inhibitors of picornavirus 3C protease in vitro.

Korea Research Institute of Chemical Technology
Structure-Based Drug Design of Potent Pyrazole Derivatives against Rhinovirus Replication.

Umr 7273 Cnrs
Pan-NS3 protease inhibitors of hepatitis C virus based on an R

Uppsala University
Design, synthesis and identification of silicon-containing HCV NS5A inhibitors with pan-genotype activity.

Chia Tai Tianqing Pharmaceutical Group
Discovery of Potent EV71 Capsid Inhibitors for Treatment of HFMD.

Wuxi Apptec (Shanghai)
Structure-based design and synthesis of macrocyclic human rhinovirus 3C protease inhibitors.

Novartis Institutes For Biomedical Research
Highlights of the Structure-Activity Relationships of Benzimidazole Linked Pyrrolidines Leading to the Discovery of the Hepatitis C Virus NS5A Inhibitor Pibrentasvir (ABT-530).

Abbvie
The discovery and optimization of naphthalene-linked P2-P4 Macrocycles as inhibitors of HCV NS3 protease.

Bristol-Myers Squibb
Structure-activity relationship of uridine-based nucleoside phosphoramidate prodrugs for inhibition of dengue virus RNA-dependent RNA polymerase.

Novartis Institute For Tropical Diseases
Synthesis and antiviral evaluation of novel peptidomimetics as norovirus protease inhibitors.

Emory University
BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE

Prelude Therapeutics
Bicyclic amines as CDK2 inhibitors

Incyte
Opioid compounds and uses thereof

Rhodes Technologies
Calcium channel inhibitors

Cavion
5-alkyl pyrrolidine orexin receptor agonists

Merck Sharp & Dohme
Imidazo[1′,2′:1,6]pyrido[2,3-d]pyrimidine compound as protein kinase inhibitor

Shengke Pharmaceuticals (Jiangsu)
Aryl ethene derivative and pharmaceutical composition containing same as active ingredient

Daegu-Gyeongbuk Medical Innovation Foundation
Imidazole and triazole containing bicyclic compounds as JAK inhibitors

Theravance Biopharma R&D Ip
Pyridazinone macrocycles as IRAK inhibitors and uses thereof

Merck Patent
Acceleration of diabetic wound healing

University of Notre Dame Du Lac
Substituted 7-azabicycles and their use as orexin receptor modulators

Janssen Pharmaceutica
Substituted pyrrolopyrimidines as HDM2 inhibitors

Merck Sharp & Dohme
Heterocyclic compounds as inhibitors of class I PI3KS

TBA
Purinone compounds as kinase inhibitors

Pharmacyclics
Btk inhibitors

Merck Sharp & Dohme
Cycloalkyl acid derivative, preparation method thereof, and pharmaceutical application thereof

Shanghai Hengrui Pharmaceutical
Autotaxin inhibitors

Novartis
Fused-bicyclic aryl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors

Forma Therapeutics
Aniline derivatives, their preparation and their therapeutic application

Sanofi
Compounds and methods of use

Medivation Technologies
Substituted indazole derivatives active as kinase inhibitiors

Nerviano Medical Sciences
Heterocyclic derivatives and their use in the treatment of neurological disorders

Novartis
Antidiabetic compounds

Merck Sharp & Dohme
Methods of treating heart failure

Amgen
Imidazolin-5-one derivative useful as FASN inhibitors for the treatment of cancer

Janssen Pharmaceutica
Substituted bicyclic compounds

Bristol-Myers Squibb
Nostotrebin 6, a bis(cyclopentenedione) with cholinesterase inhibitory activity isolated from Nostoc sp. str. Lukesová 27/97.

Brno University of Technology
Selective β-glucuronidase inhibitors as a treatment for side effects of camptothecin antineoplastic agents

University of North Carolina At Chapel Hill
Synthesis, in vitro evaluation and molecular docking studies of novel amide linked triazolyl glycoconjugates as new inhibitors of a-glucosidase.

Csir-Indian Institute of Chemical Biology
Small Molecules Engage Hot Spots through Cooperative Binding To Inhibit a Tight Protein-Protein Interaction.

Indiana University School of Medicine
Synthesis, structure-activity relationships studies of benzoxazinone derivatives as a-chymotrypsin inhibitors.

University of Karachi
Cyclic amides

Hoffmann-La Roche
Method for the treatment of pompe disease using 1-deoxynojirimycin and derivatives

Amicus Therapeutics
2-substituted-3-phenylpropionic acid derivatives and their use in the treatment of inflammatory bowel disease

Albireo
Functionally selective ligands of dopamine D2 receptors

University of North Carolina At Chapel Hill
5,8-dihydro-6H-pyrazolo[3,4-h]quinazolines as IGF-1R/IR inhibitors

Boehringer Ingelheim International
Imidazopyridazinyl compounds

Bristol-Myers Squibb
Inhibitors of bruton's tyrosine kinase

Pharmacyclics
Compounds from Antrodia cinnamomea and use thereof

Simpson Biotech
Pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as mTOR inhibitors

Kudos Pharmaceuticals
Esters of (acyloxymethyl)acrylamide, a pharmaceutical composition containing them, and their use as inhibitors of the thioredoxin—thioredoxin reductase system

Instytut Chemii Organicznej Polskiej Akademii Nauk
A photorhabdus natural product inhibits insect juvenile hormone epoxide hydrolase.

Goethe Universität Frankfurt
Pyrazolo[3,4-d]pyrimidine compounds and their use as PDE2 inhibitors and/or CYP3A4 inhibitors

Pfizer
Isoform-specific inhibition of cyclophilins.

Max Planck Research
Competitive inhibition of human poly(A)-specific ribonuclease (PARN) by synthetic fluoro-pyranosyl nucleosides.

University of Thessaly
Developing dual and specific inhibitors of dimethylarginine dimethylaminohydrolase-1 and nitric oxide synthase: toward a targeted polypharmacology to control nitric oxide.

The University of Texas
Receptor affinities of dopamine D1 receptor-selective novel phenylbenzazepines.

Harvard University
Affinity of cyamemazine, an anxiolytic antipsychotic drug, for human recombinant dopamine vs. serotonin receptor subtypes.

Aventis Pharma
Cloning and pharmacological characterization of the rat CB(2) cannabinoid receptor.

Virginia Commonwealth University
Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis.

St. Bartholomew'S and The Royal London School of Medicine and Dentistry
Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells.

Kyoto University
Molecular cloning and expression of a 5-hydroxytryptamine7 serotonin receptor subtype.

National Institute of Neurological Disorders and Stroke
RS 39604: a potent, selective and orally active 5-HT4 receptor antagonist.

Syntex Discovery Research
Receptor binding profiles of amiloride analogues provide no evidence for a link between receptors and the Na+/H+ exchanger, but indicate a common structure on receptor proteins.

Center For Bio-Pharmaceutical Sciences
Acyclic, orally bioavailable ketone-based cathepsin K inhibitors.

Gsk
Carbonic anhydrase inhibitors. Inhibition of mitochondrial isozyme V with aromatic and heterocyclic sulfonamides.

Universita Degli Studi Di Firenze
1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazoles: identification of a potent aurora kinase inhibitor with a favorable antitumor kinase inhibition profile.

Nerviano Medical Sciences
3-(4-[[Benzyl(methyl)amino]methyl]phenyl)-6,7-dimethoxy-2H-2-chromenone (AP2238) inhibits both acetylcholinesterase and acetylcholinesterase-induced beta-amyloid aggregation: a dual function lead for Alzheimer's disease therapy.

University of Bologna
Bis-huperzine B: highly potent and selective acetylcholinesterase inhibitors.

Shanghai Institute of Materia Medica
Novel, potent and selective cyclin D1/CDK4 inhibitors: indolo[6,7-a]pyrrolo[3,4-c]carbazoles.

Eli Lilly
Nonpeptidic potent HIV-1 protease inhibitors: (4-hydroxy-6-phenyl-2-oxo-2H- pyran-3-yl)thiomethanes that span P1-P2' subsites in a unique mode of active site binding.

Parke-Davis Pharmaceutical Research
Computer-aided design, synthesis, and anti-HIV-1 activity in vitro of 2-alkylamino-6-[1-(2,6-difluorophenyl)alkyl]-3,4-dihydro-5-alkylpyrimidin-4(3H)-ones as novel potent non-nucleoside reverse transcriptase inhibitors, also active against the Y181C variant.

Sapienza University of Rome
Novel indolyl aryl sulfones active against HIV-1 carrying NNRTI resistance mutations: synthesis and SAR studies.

Sapienza University of Rome
5H-pyrrolo[1,2-b] [1,2,5]benzothiadiazepines (PBTDs): a novel class of non-nucleoside reverse transcriptase inhibitors.

Sapienza University of Rome